LncRNA ZNF593-AS offers hope for heart disease treatment

The research presented in the article delves into the regulatory role of the long non-coding RNA (lncRNA) ZNF593-AS in cardiac hypertrophy and myocardial remodeling, processes that are pivotal in the progression of heart failure and other cardiovascular diseases. The study uncovers how ZNF593-AS exerts its inhibitory effects by upregulating the expression of Mitofusin 2 (Mfn2), a protein known for its role in the regulation of mitochondrial dynamics and cellular metabolism.

Sanofi enters vaccine licensing deal with Novavax, giving beleaguered biotech a lifeline

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said

May 10, 2024

BGI Genomics report: Thailand needs to take urgent action to combat cervical cancer

Only 28.5% of Thai women are diagnosed at stage I of cervical cancer when survival rates are highest, according to a study published by the

August 1, 2023

Elucid wins FDA 510(k) nod for heart plaque image analysis software

Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Elucid received 510(k) clearance from the

October 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.